Prophylactic ECMO during TAVI in patients with depressed left ventricular ejection fraction.
Aged
Aged, 80 and over
Aortic Valve
/ surgery
Aortic Valve Stenosis
/ complications
Echocardiography
Extracorporeal Membrane Oxygenation
/ methods
Female
Follow-Up Studies
Germany
/ epidemiology
Humans
Intraoperative Care
/ methods
Male
Retrospective Studies
Risk Factors
Stroke Volume
/ physiology
Survival Rate
/ trends
Time Factors
Transcatheter Aortic Valve Replacement
/ methods
Treatment Outcome
Ventricular Dysfunction, Left
/ etiology
Ventricular Function, Left
/ physiology
Aortic stenosis
Depressed left ventricular function
ECMO
Multidisciplinary Heart Team
TAVI
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
20
06
2018
accepted:
23
08
2018
pubmed:
30
8
2018
medline:
6
6
2019
entrez:
30
8
2018
Statut:
ppublish
Résumé
This study investigated the impact of prophylactic veno-arterial extracorporeal membrane oxygenation (pECMO) in patients with depressed left ventricular ejection fraction (dLVEF) undergoing transcatheter aortic valve implantation (TAVI). Out of 1490 patients undergoing TAVI at two centers (2010-2015), 222 patients had dLVEF (≤ 40%). Of these, 21 patients (10%) underwent TAVI with pECMO. Complications and outcome according to pECMO were analyzed in the entire and in a propensity-matched population. In the entire population, patients with pECMO had a higher logEuroScore I (33% ± 19 vs. 25% ± 17; p = 0.037), worse LVEF (26% ± 7 vs. 32% ± 7; p = 0.001), more major bleedings (29% vs. 9%; p = 0.015), higher transfusion rate (30% vs. 10%; p = 0.019) and longer in-hospital stay (9.0 [7.0;14.0] vs. 7.0 [5.0;10.0] days; p = 0.024). After propensity matching only transfusion rate remained higher with pECMO (30% vs. 7%; p = 0.025). In the entire population, rate and risk of 30-day mortality was higher with pECMO (24% vs. 6%, HR 95%CI 4.29 [1.51-12.19]; p = 0.006). In the matched population, this effect was attenuated (24% vs. 12%, HR 95%CI 2.09 [0.61-7.23]; p = 0.243). Cumulative rate and risk of 1-year mortality did not differ in the entire (log-rank p = 0.069; 39% vs. 22%, HR 95%CI 1.99 [0.94-4.24]; p = 0.074) nor in the matched population (log-rank p = 0.520; 39% vs. 31%, HR 95%CI 1.34 [0.55-3.28]; p = 0.523). In patients with dLVEF undergoing TAVI, periprocedural pECMO support does not seem to improve patient outcome.
Sections du résumé
BACKGROUND
BACKGROUND
This study investigated the impact of prophylactic veno-arterial extracorporeal membrane oxygenation (pECMO) in patients with depressed left ventricular ejection fraction (dLVEF) undergoing transcatheter aortic valve implantation (TAVI).
METHODS
METHODS
Out of 1490 patients undergoing TAVI at two centers (2010-2015), 222 patients had dLVEF (≤ 40%). Of these, 21 patients (10%) underwent TAVI with pECMO. Complications and outcome according to pECMO were analyzed in the entire and in a propensity-matched population.
RESULTS
RESULTS
In the entire population, patients with pECMO had a higher logEuroScore I (33% ± 19 vs. 25% ± 17; p = 0.037), worse LVEF (26% ± 7 vs. 32% ± 7; p = 0.001), more major bleedings (29% vs. 9%; p = 0.015), higher transfusion rate (30% vs. 10%; p = 0.019) and longer in-hospital stay (9.0 [7.0;14.0] vs. 7.0 [5.0;10.0] days; p = 0.024). After propensity matching only transfusion rate remained higher with pECMO (30% vs. 7%; p = 0.025). In the entire population, rate and risk of 30-day mortality was higher with pECMO (24% vs. 6%, HR 95%CI 4.29 [1.51-12.19]; p = 0.006). In the matched population, this effect was attenuated (24% vs. 12%, HR 95%CI 2.09 [0.61-7.23]; p = 0.243). Cumulative rate and risk of 1-year mortality did not differ in the entire (log-rank p = 0.069; 39% vs. 22%, HR 95%CI 1.99 [0.94-4.24]; p = 0.074) nor in the matched population (log-rank p = 0.520; 39% vs. 31%, HR 95%CI 1.34 [0.55-3.28]; p = 0.523).
CONCLUSION
CONCLUSIONS
In patients with dLVEF undergoing TAVI, periprocedural pECMO support does not seem to improve patient outcome.
Identifiants
pubmed: 30155732
doi: 10.1007/s00392-018-1364-6
pii: 10.1007/s00392-018-1364-6
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
366-374Références
Psychol Methods. 2004 Dec;9(4):403-25
pubmed: 15598095
Circulation. 2006 Apr 11;113(14):1738-44
pubmed: 16585393
J Am Coll Cardiol. 2008 Apr 15;51(15):1466-72
pubmed: 18402902
J Am Coll Cardiol. 2009 May 19;53(20):1865-73
pubmed: 19442886
Artif Organs. 2009 Sep;33(9):696-703
pubmed: 19775261
Circulation. 2011 Jan 25;123(3):299-308
pubmed: 21220731
N Engl J Med. 2011 Jun 9;364(23):2187-98
pubmed: 21639811
J Am Coll Cardiol. 2012 Mar 27;59(13):1200-54
pubmed: 22300974
JACC Cardiovasc Interv. 2012 May;5(5):552-559
pubmed: 22625194
J Thorac Cardiovasc Surg. 2013 Jan;145(1):6-23
pubmed: 23084102
Eur J Cardiothorac Surg. 2013 Sep;44(3):478-84; discussion 484
pubmed: 23389474
Catheter Cardiovasc Interv. 2013 Oct 1;82(4):E542-51
pubmed: 23554044
Int J Cardiol. 2013 Oct 9;168(4):3431-8
pubmed: 23688431
Eur J Cardiothorac Surg. 2015 Jan;47(1):24-30; discussion 30
pubmed: 24627439
Heart Lung Circ. 2014 Oct;23(10):957-62
pubmed: 24954708
Eur Heart J. 2014 Oct 7;35(38):2627-38
pubmed: 25062952
EuroIntervention. 2014 Nov;10(7):842-9
pubmed: 25415151
EuroIntervention. 2014 Nov;10(7):850-9
pubmed: 25415152
JACC Cardiovasc Imaging. 2015 Mar;8(3):380-2
pubmed: 25459306
Catheter Cardiovasc Interv. 2015 Aug;86(2):316-22
pubmed: 25546704
Am J Respir Crit Care Med. 2015 Apr 15;191(8):894-901
pubmed: 25695688
Clin Res Cardiol. 2016 Mar;105(3):273-8
pubmed: 26395021
Am J Cardiol. 2015 Nov 15;116(10):1574-80
pubmed: 26434512
Clin Res Cardiol. 2016 Apr;105(4):283-96
pubmed: 26608160
Clin Res Cardiol. 2017 Jun;106(6):411-419
pubmed: 28078447
Clin Res Cardiol. 2017 Dec;106(12):1018-1025
pubmed: 28828679
JACC Cardiovasc Interv. 2017 Oct 23;10(20):2078-2087
pubmed: 29050625
Catheter Cardiovasc Interv. 2018 Jul;92(1):149-156
pubmed: 29130616
J Am Coll Cardiol. 2018 Mar 27;71(12):1297-1308
pubmed: 29566812
Clin Res Cardiol. 2018 Aug;107(Suppl 2):81-87
pubmed: 29951801